Clinical trial · Observational
Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colo-rectal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- CRC Cases
- description
- Individuals with histologically confirmed colorectal adenocarcinoma
- label
- Controls
- description
- Individuals with negative colonoscopy results and no history of colorectal cancer
Primary outcomes (1)
- measure
- Sensitivity and Specificity of delta-HLD Technology for Colorectal Cancer
- timeFrame
- Within 3 months after sample collection
- description
- Diagnostic performance of methylation biomarkers detected using delta-HLD technology in plasma and tissue samples, using colonoscopy and histopathology as the clinical reference standard.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Candidate for colonoscopy or colorectal surgery * Willing and able to provide informed consent * Able to provide blood and/or tissue sample before treatment or resection Exclusion Criteria: * Prior history of colorectal cancer * Inflammatory bowel disease * Known hereditary cancer syndromes (e.g., Lynch, FAP) * Other active malignancies * Recent chemotherapy or immunosuppressive treatment
References
Publications (0)
Data not yet available